Triple Negative Breast Cancer
Conditions
Brief summary
Predictive biomarkers of response to combination chemotherapy and immune-checkpoint inhibitors are urgently needed to help tailor treatment recommendations for patients with early-stage TNBC. Tumour-associated microbiota in primary breast tumours represent promising and novel candidate biomarkers modulators of the efficacy of therapies for patients with TNBC. It has been shown that microbes colonizing breast tumours can modulate the efficacy of commonly used drugs and that the microbiome of breast tissue biopsies could represent a new biomarker. Data on the microbiome of patients with cancer indicate the potential for a new class of bacteria-based oncological biomarkers, for exploitation in precision oncology.
Interventions
None listed
Sponsors
University College Cork
Breast Cancer Research Foundation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Be willing and able to provide written informed consent for the trial in accordance with national/local guidelines. 2. Be a male or female subject 18 years of age on day of signing informed consent. 3. Histologically proven infiltrating carcinoma of the breast on core needle biopsy that is: HER2 negative in primary tumour pre-treatment by local pathology assessed according current ASCO/CAP guidelines: In situ hybridization non-amplified (ratio of HER2 to CEP17 \< 2.0 or single probe average HER2 gene copy number \< 4 signals/cell), OR Immunohistochemistry (IHC) 0 or IHC 1+. ER and PR negative in primary tumour pre-treatment defined as \< 10% of cells expressing hormonal receptors via IHC analysis by local laboratory assessment. 4. Unresected, untreated breast cancer planned to undergo neoadjuvant systemic therapy, that meets one of the following clinical stages (see Appendix A): o T2, T3, or T4a-d lesion, any N, M0 5. Be willing to undergo mandatory research biopsy procedure at baseline (up to 4 core samples may be taken from this procedure).
Exclusion criteria
1. Patients who are pregnant or breast-feeding 2. Current use of any investigational agents 3. History or current evidence of any condition, therapy, lab abnormality or other circumstance that in the opinion of the investigator might expose the subject to risk by participating in the trial, confound the results of the trial, or interfere with the subject's participation for the full duration of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the breast cancer microbiome pre- and post-therapy, in patients with early stage TNBC undergoing neoadjuvant systemic therapy | Through study completion, an average of 1 year | Microbiome evaluation with metagenomic sequencing to assess changes in the relative abundance of microbial taxa (measured as percentage abundance per microbial species and changes in percentage abundance between baseline and post-therapy timepoints) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To examine the relationship between the local breast cancer microbiome in early-stage triple negative breast cancer and pathologic complete response | Through study completion, an average of 1 year | Correlation between breast microbiome composition (measured as percent abundance of microbial taxa derived from metagenomic sequencing) and pathologic complete response rate (pCR) |
| To examine the relationship between the local breast cancer microbiome in early-stage triple negative breast cancer and event-free survival | Through study completion, an average of 1 year | Correlation between breast microbiome composition (measured as percent abundance of microbial taxa derived from metagenomic sequencing) and event free survival (EFS) |
| To examine the relationship between the local breast cancer microbiome in early-stage triple negative breast cancer and overall survival | Through study completion, an average of 1 year | Correlation between breast microbiome composition (measured as percent abundance of microbial taxa derived from metagenomic sequencing) and overall survival (OS) |
| To determine the relationship between the breast cancer microbiome and tumor infiltrating leukocytes (TILs) | Through study completion, an average of 1 year | Correlation between breast microbiome composition (measured as percent abundance of microbial taxa derived from metagenomic sequencing) and TILS (\<50% versus ≥50%) |
| To determine the relationship between the breast cancer microbiome and programmed death ligand -1 (PDL-1) | Through study completion, an average of 1 year | Correlation between breast microbiome composition (measured as percent abundance of microbial taxa derived from metagenomic sequencing) and , PDL1 (positive defined as CPS ≥ 1 by PD-L1 IHC 22C3 assay versus negative) |
| To evaluate the gut microbiome pre- and post-therapy, in patients with early stage TNBC undergoing neoadjuvant systemic therapy | Through study completion, an average of 1 year | Change in the gut microbiome composition (measured as percent abundance of microbial taxa derived from metagenomic sequencing) between pre- and post-therapy |
Countries
Ireland
Contacts
CONTACTRoisin Connolly
Outcome results
None listed